Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kerendia
Pharma
JPM25: Bayer gears up for 'must-win battles' amid Xarelto decline
Potential launches of the ATTR-CM drug acoramidis and the menopause med elinzanetant are what Stefan Oelrich called “must-win battles” at Bayer.
Angus Liu
Jan 15, 2025 8:00pm
Wegovy and Zepbound tipped to fuel $20B heart failure boom
Jan 7, 2025 11:12am
Bayer's 'transition year' looms as Xarelto sales falter
Nov 12, 2024 3:03pm
Bayer touts results for Kerendia in phase 3 heart failure trial
Sep 2, 2024 1:00am
Bayer charts growth course amid Xarelto's ongoing sales descent
Aug 6, 2024 12:29pm
Bayer's Kerendia excels in P3 trial of heart failure patients
Aug 5, 2024 10:24am
